MAR 21, 2022 3:00 AM PDT

New Combination Therapy Effective in Hormone Sensitive Prostate Cancer

WRITTEN BY: Katie Kokolus

Like all cancers, prostate cancer has many classifications and subtypes. One such type is metastatic, hormone-sensitive prostate cancer (mHSPC).  Standard of care for patients with mHSPC includes androgen-deprivation therapy (ADT). Since prostate cancer growth is fueled by male sex hormones, collectively known as androgens, hindering their production or preventing them from reaching cancer cells can slow tumor progression. In addition to ADT, the treatment regimen for mHSPC patients includes either docetaxel, a taxane-based chemotherapy, or an androgen receptor antagonists, also referred to as anti-androgens or androgen receptor blockers, which block androgens from binding the cancer cell. A class of anti-androgen drugs is known as “next-generation” androgen receptor pathway inhibitors include FDA-approved drugs darlutamide, abiraterone, enzalutamide, apalutamide.    

Notably, recent phase 3 clinical trials have shown that several drugs can provide a survival benefit for mHSPC. The combination of ADT with chemotherapy docetaxel extends survival. Similarly, separate clinical trials have investigated the next-generation androgen receptor pathway inhibitors, and each (darolutamide, abiraterone, enzalutamide, apalutamide) improved the efficacy of ADT alone. 

Recently, a group of investigators explored whether a triple combination regimen of docetaxel, ADT, and an androgen receptor pathway inhibitor could provide added efficacy. Their findings were published in the New England Journal of Medicine. The study was named “Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer” (ARASENS; NCT02799602). ARASENS is an international, phase 3 trial in which mHSPC patients were randomized to receive ADT and docetaxel plus darolutamide (N=651) or ADT and docetaxel plus placebo (N=655).  

At the time of analysis, the study enrolled 1306 mHSPC patients (control group- N=655, darolutamide group- N=651).  The researchers found the risk of death 32.5% lower for patients in the darolutamide group than the placebo group.  Side effects were similar in the two groups indicating that the combination of three therapies did not increase the toxicity of the regimen. 

Overall, the large clinical trial, involving almost 300 international hospital sites, demonstrated that mHSPC patients benefit from adding darolutamide to standard treatment consisting of docetaxel and ADT.  This clinical combination appears to be a life-extending therapy that could significantly improve survivorship for mHSPC patients.  Additionally, exploring this combination in other subsets of prostate cancer could extend the use of its therapeutic potential. 

 

Sources: Oncol Ther, Drugs Aging, Annal Oncol, N Eng J Med, Lancet Oncol, N Eng J Med, J Clin Oncol, N Eng J Med

 

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
APR 14, 2022
Cancer
April is Oral Cancer Awareness Month
APR 14, 2022
April is Oral Cancer Awareness Month
All cancers that affect the oral cavity and back of the throat, known as the oropharyngeal, are grouped as Oral Can ...
APR 25, 2022
Cancer
Exercise Reduces Proliferation of Colon Cancer Cells
APR 25, 2022
Exercise Reduces Proliferation of Colon Cancer Cells
Substantial evidence supports the association between exercise and reduced risk of colon cancer.  Physical act ...
APR 26, 2022
Immunology
Unraveling the Mystery of an Immune Cell Checkpoint
APR 26, 2022
Unraveling the Mystery of an Immune Cell Checkpoint
The immune system can get tired when it has to fight against a chronic infection or a disease like cancer. Exhausted T c ...
MAY 12, 2022
Cancer
Crisis in Ukraine Disrupts Delivery of Critical Cancer Care
MAY 12, 2022
Crisis in Ukraine Disrupts Delivery of Critical Cancer Care
Many factors including the type of cancer, pathologic stage, and the general health and demographics of the patient, dic ...
JUN 06, 2022
Drug Discovery & Development
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
JUN 06, 2022
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
Weight loss achieved via bariatric surgery among adults with obesity is linked to a lower risk of developing cancer and ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
Loading Comments...